Cargando…
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
Despite pre-clinical murine data supporting T regulatory (Treg) cell depletion as a major mechanism by which anti-CTLA-4 antibodies function in vivo, the two main antibodies tested in patients (ipilimumab and tremelimumab) have failed to demonstrate similar effects. We report analogous findings in a...
Autores principales: | Knorr, David, Leidner, Rom, Jensen, Shawn, Meng, Ryan, Jones, Andrew, Ballesteros-Merino, Carmen, Bell, R. Bryan, Baez, Maria, Sprott, David, Bifulco, Carlo, Piening, Brian, Dahan, Rony, Fox, Bernard A., Ravetch, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884505/ https://www.ncbi.nlm.nih.gov/pubmed/36711504 http://dx.doi.org/10.1101/2023.01.19.522856 |
Ejemplares similares
-
Mechanisms of Flucytosine Resistance in Cryptococcus gattii May Be Independent of the FCY2-FCY1-FUR1 Pathway
por: Vu, Kiem, et al.
Publicado: (2017) -
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
por: Li, Fubin, et al.
Publicado: (2012) -
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
por: Falchook, Gerald S., et al.
Publicado: (2016) -
Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB(−/−) Mice
por: Bolland, Silvia, et al.
Publicado: (2002) -
FcγRIIB is a T cell checkpoint in antitumor immunity
por: Farley, Clara R., et al.
Publicado: (2021)